Comparative Pharmacology
Head-to-head clinical analysis: EMFLAZA versus ILUVIEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMFLAZA versus ILUVIEN.
EMFLAZA vs ILUVIEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
Fluocinolone acetonide, a corticosteroid, suppresses inflammation by inhibiting phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. It also inhibits cytokine production and endothelial cell adhesion molecule expression.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
Intravitreal implant containing 0.19 mg fluocinolone acetonide, designed to release drug over approximately 36 months. Administered as a single injection into the vitreous cavity of the eye.
None Documented
None Documented
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
Intravitreal terminal half-life of fluocinolone acetonide from the Iluvien implant is approximately 30 months (range 18-36 months), providing sustained release over 36 months in the vitreous cavity.
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Fluocinolone acetonide is primarily eliminated via hepatic metabolism and subsequent fecal/biliary excretion. Approximately 50-70% of a dose is excreted in feces as metabolites, with less than 20% recovered in urine as unchanged drug or metabolites.
Category C
Category C
Corticosteroid
Corticosteroid